Measuring how common neovascular AMD, diabetic macular edema, and retinal vein occlusion are in Germany using health insurance data
Official title: DATA-INSIGHT: Data Analysis for Treatment Assessment and Evaluation of New Sources for Evidence Generation in German Healthcare System
Run by Bayer · NCT07308639 · Data updated 2026-11-12
This project will use two large German health databases from 2009–2024 to find out how often people with nAMD, DME, or RVO are diagnosed and how many people currently have these conditions in Germany.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50000 (estimated) |
| Sponsor | Bayer Industry-sponsored |
| Locations | 1 site (Leverkusen) |
| Status | Recruiting |
| Started | March 3, 2026 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | June 22, 2026 |
| Trial ID | NCT07308639 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Included records represent German residents with statutory or private health insurance who have at least one recorded diagnosis of nAMD (age ≥50) or DME/RVO (age ≥18) between 2009 and 2024.
✕Probably not a fit
People without diagnoses recorded in FDZ or FDGP, residents outside Germany, or those whose care falls outside the 2009–2024 timeframe will not be represented and are unlikely to benefit directly from this analysis.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational analysis uses anonymized insurance records from two nationwide German datasets (FDZ and FDGP) covering 2009–2024 to estimate incidence and prevalence of nAMD, DME, and RVO. Researchers will identify patients with at least one relevant diagnosis code and compare counts, rates, and temporal trends between the two data sources. The work will apply age criteria (nAMD ≥50 years; DME and RVO ≥18 years) and will capture markers of care such as recorded anti-VEGF medication use when available. The project will also examine methodological differences between FDZ and FDGP to understand how data collection and coding affect disease estimates.
Why it matters
Potential benefit: If successful, the results could help clinicians and health planners better understand disease burden and target resources and treatments where they are most needed.
How similar studies have gone: Previous large administrative-database studies have produced useful incidence and prevalence estimates for these retinal diseases, but direct side-by-side comparisons of two national German datasets are less common and add a novel methodological angle.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * At least one diagnosis of nAMD, DME and RVO in the timeframe 01 JAN 2009 until 31 DEC 2024 * nAMD patients aged ≥ 50 years * DME patients aged ≥18 years * RVO patients aged ≥18 years * Participants living in Germany covered by statutory health insurance or private health insurance Exclusion Criteria: * none
Where it's running
-
Bayer Vital GmbH
Leverkusen, Germany Recruiting
Study contacts
- Study coordinator: Bayer Clinical Trials Contact
- Email: clinical-trials-contact@bayer.com
- Phone: (+)1-888-84 22937
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.